gilteritinib   Click here for help

GtoPdb Ligand ID: 8708

Synonyms: ASP-2215 | ASP2215 | Xospata®
Approved drug PDB Ligand
gilteritinib is an approved drug (FDA (2018), EMA (2019))
Compound class: Synthetic organic
Comment: Gilteritinib is an orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-related tyrosine kinase 3 (FLT3), AXL and anaplastic lymphoma kinase (ALK) [4], with clinical antineoplastic activity. Gilteritinib inhibits the activity of FLT3-activating mutations which are one of the most common genetic alterations in acute myeloid leukemia (AML).

SARS-CoV-2: AXL is a kinase upstream of p38 MAP kinases. p38 activity has been reported to be upregulated following SARS-CoV-2 infection of host cells in vitro, and gilteritinib produces an antiviral effect (IC50= 807 nM) [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 10
Hydrogen bond donors 3
Rotatable bonds 9
Topological polar surface area 121.11
Molecular weight 552.35
XLogP 2.44
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES COc1cc(ccc1N1CCC(CC1)N1CCN(CC1)C)Nc1nc(NC2CCOCC2)c(nc1C(=O)N)CC
Isomeric SMILES COc1cc(ccc1N1CCC(CC1)N1CCN(CC1)C)Nc1nc(NC2CCOCC2)c(nc1C(=O)N)CC
InChI InChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34)
No information available.
Summary of Clinical Use Click here for help
The FDA granted Fast Track/Priority Review designation for the New Drug Application (NDA) that was submitted by the drug's developer Astellas in June 2018. This led to full approval in November 2018, for the use of gilteritinib (Xospata®) as a therapy for patients with relapsed/refractory acute myeloid leukemia (AML) with a confirmed FLT3 mutation. Phase 1/2 clinical trial results were published by Perl et al. in 2017 [5]. The EMA had granted gilteritinib orphan drug designation as a treatment for AML in January 2018 [2]. In September 2019, following accelerated assessment, the EMA Committee for Medicinal Products for Human Use (CHMP) reported that they were minded to grant marketing authorisation for the same patient group as indicated by the FDA approval [3], and full approval was granted in October 2019.